Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Julie Johnson

Physician Assistant Ashburn, VA Physician Assistant

NPI 1568512465 CMS profile 10500238

45155 Research Pl, Suite 140, Ashburn, VA 20147

Open in the dashboard

General payments

$22,357

753 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Julie Johnson of Ashburn, VA is reported in the CMS Open Payments database as having received $22,357 across 753 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,512 208
2024 General $5,675 177
2023 General $4,644 171
2022 General $2,374 83
2021 General $2,152 114

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Julie Johnson
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Julie Johnson were reported at $7,512. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Julie Johnson Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,152 $132 $37–$438 $132
2022 $2,374 $155 $48–$522 $149
2023 $4,644 $167 $52–$557 $160
2024 $5,675 $178 $55–$600 $164
2025 $7,512 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,658 134 payments
  2. UCB, Inc. $2,200 31 payments
  3. Regeneron Healthcare Solutions, Inc. $1,830 48 payments
  4. Genzyme Corporation $1,613 34 payments
  5. Amgen Inc. $1,578 45 payments
  6. Galderma Laboratories, L.P. $1,533 68 payments
  7. Novartis Pharmaceuticals Corporation $1,308 52 payments
  8. Sun Pharmaceutical Industries Inc. $1,250 36 payments
  9. LEO Pharma Inc. $1,084 43 payments
  10. Lilly USA, LLC $1,027 37 payments
  11. Other $5,276 225 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $20,690 744 payments
  2. Consulting Fee $1,140 1 payment
  3. Education $527 8 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $2,164 46 payments
  2. RINVOQ $2,085 64 payments
  3. Bimzelx $2,035 23 payments
  4. Otezla $1,578 45 payments
  5. DUPIXENT Inflammation And Immunology $1,404 33 payments
  6. ADBRY $1,055 42 payments
  7. SKYRIZI $1,051 46 payments
  8. TREMFYA $1,045 39 payments
  9. COSENTYX $689 30 payments
  10. CIBINQO $662 41 payments
  11. Other $10,470 476 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

542

Median for Physician Assistant: 241

Drug cost

$23,664

Median for Physician Assistant: $4,110

Branded share of claims

7.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pimecrolimus Generic 17 $7,097
Fluocinolone Acetonide Fluocinolone/Shower Cap Brand 27 $1,971
Ciclopirox Generic 48 $1,958
Ivermectin Generic 14 $1,952
Fluocinonide Generic 32 $1,751
Clobetasol Propionate Generic 36 $1,571
Metronidazole Generic 20 $1,292
Betamethasone Dipropionate Generic 32 $923
Triamcinolone Acetonide Generic 66 $747
Ammonium Lactate Generic 33 $736

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$74,181

Of which drugs: $327

Medicare patients

474

Average age 74

Services billed

2,293

339 women, 135 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 49%
Diabetes 26%
Depression 20%
Chronic kidney disease 19%
Osteoporosis 19%
Ischemic heart disease 17%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 13 29 $19

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$762 — —
RINVOQ
$730 — —
Otezla
$700 — —
COSENTYX
$496 — —
Bimzelx
$325 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

753 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record